{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:34Z","timestamp":1780987954962,"version":"3.54.1"},"reference-count":130,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This article summarizes current targeted therapies that have received regulatory approval for the treatment of B- and T-cell lymphomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Over the last 20 years, new drug therapies for lymphomas of B cells and T cells have expanded considerably. Targeted therapies for B-cell lymphomas include: (1) monoclonal antibodies directed at the CD20 lymphocyte antigen, examples of which are rituximab, ofatumumab, and obinutuzumab; (2) gene transfer therapy, an example of which is chimeric antigen receptor\u2013modified T-cell (CAR-T) therapy directed at the CD19 antigen expressed on the cell surface of both immature and mature B cells; and (3) small-molecule inhibitors (ibrutinib, acalabrutinib, copanlisib, duvelisib, and idelalisib) that target the B-cell receptor signaling pathway. Of note, brentuximab vedotin is an antibody\u2013drug conjugate that targets CD30, another lymphocyte antigen expressed on the cell surface of both Hodgkin lymphoma (a variant of B-cell lymphoma) and some T-cell lymphomas. Although aberrant epigenetic signaling pathways are present in both B- and T-cell lymphomas, epigenetic inhibitors (examples include belinostat, vorinostat, and romidepsin) are currently approved by the Food and Drug Administration for T-cell lymphomas only. In addition, therapies that target the tumor microenvironment have been developed. Examples include mogamulizumab, bortezomib, lenalidomide, nivolumab, and pembrolizumab. In summary, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The therapeutic landscape of lymphomas has continued to evolve. In turn, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Further opportunities are warranted to identify patients who are most likely to achieve durable response and reduce the risk of disease progression. Ongoing trials with current and investigational agents may further elucidate their place in therapy and therapeutic benefits.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxz202","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T15:02:19Z","timestamp":1570114939000},"page":"1825-1834","source":"Crossref","is-referenced-by-count":28,"title":["Current targeted therapies in lymphomas"],"prefix":"10.1093","volume":"76","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Houston Methodist Baytown Hospital, Baytown, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"2019103013422116500_CIT0001","author":"National Comprehensive Cancer Network"},{"key":"2019103013422116500_CIT0002","author":"National Comprehensive Cancer Network"},{"key":"2019103013422116500_CIT0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0889-8588(18)30390-3","article-title":"Immunologic markers in non-Hodgkin\u2019s lymphoma","volume":"5","author":"Freedman","year":"1991","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019103013422116500_CIT0004","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood."},{"key":"2019103013422116500_CIT0005","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood."},{"key":"2019103013422116500_CIT0006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother."},{"key":"2019103013422116500_CIT0007","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood."},{"key":"2019103013422116500_CIT0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev."},{"key":"2019103013422116500_CIT0010","doi-asserted-by":"crossref","unstructured":"Morschhauser F , FeugierP, FlinnIWet al Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI study. Paper presented at 2018 American Society of Hematology Annual Meeting. San Diego, CA; 2018 Dec 8. https:\/\/ash.confex.com\/ash\/2018\/webprogram\/Paper118519.html","DOI":"10.1182\/blood-2018-99-118519"},{"key":"2019103013422116500_CIT0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IGG FC receptor Fcgammariiia gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"key":"2019103013422116500_CIT0012","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment","volume":"273","author":"Deans","year":"1998","journal-title":"J Biol Chem."},{"key":"2019103013422116500_CIT0013","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood."},{"key":"2019103013422116500_CIT0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun."},{"key":"2019103013422116500_CIT0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"Van Meerten","year":"2010","journal-title":"Semin Hematol."},{"key":"2019103013422116500_CIT0016","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol."},{"key":"2019103013422116500_CIT0017","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol."},{"key":"2019103013422116500_CIT0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica."},{"key":"2019103013422116500_CIT0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","volume":"2007","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019103013422116500_CIT0021","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0022","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia."},{"key":"2019103013422116500_CIT0023","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0024","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood.V110.11.2348.2348","article-title":"GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior antitumor efficacy and superior tissue B cell depletion in vivo","volume":"110","author":"Umana","year":"2007","journal-title":"Blood"},{"key":"2019103013422116500_CIT0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1586\/14737140.6.6.861","article-title":"Ibritumomab tiuxetan for non-Hodgkin\u2019s lymphoma","volume":"6","author":"Johnston","year":"2006","journal-title":"Expert Rev Anticancer Ther."},{"key":"2019103013422116500_CIT0026","author":"Clinicaltrials.gov."},{"key":"2019103013422116500_CIT0027","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/14712598.2010.504707","article-title":"I-131 tositumomab","volume":"10","author":"William","year":"2010","journal-title":"Expert Opin Biol Ther."},{"key":"2019103013422116500_CIT0028","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0029","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-lineindolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0030","author":"Office of the Federal Register"},{"key":"2019103013422116500_CIT0031","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11899-016-0345-y","article-title":"CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas","volume":"11","author":"Bhatt","year":"2016","journal-title":"Curr Hematol Malig Rep."},{"key":"2019103013422116500_CIT0032","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0033","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther."},{"key":"2019103013422116500_CIT0034","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/13543784.2011.542147","article-title":"Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells","volume":"20","author":"Ansell","year":"2011","journal-title":"Expert Opin Investig Drugs."},{"key":"2019103013422116500_CIT0035","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl."},{"key":"2019103013422116500_CIT0036","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotechnol."},{"key":"2019103013422116500_CIT0037","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(16)30404-1","article-title":"Brentuximab vedotin for CD30-positive tumours","volume":"17","author":"Masuda","year":"2016","journal-title":"Lancet Oncol."},{"key":"2019103013422116500_CIT0038","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer."},{"key":"2019103013422116500_CIT0039","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol."},{"key":"2019103013422116500_CIT0040","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0041","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0042","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"key":"2019103013422116500_CIT0043","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0044","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0045","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0046","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nri1729","article-title":"Supernatural T cells: genetic modification of T cells for cancer therapy","volume":"5","author":"Kershaw","year":"2005","journal-title":"Nat Rev Immunol."},{"key":"2019103013422116500_CIT0047","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2019103013422116500_CIT0048","volume-title":"Kymriah (tisagenlecleucel) prescribing information","year":"2018"},{"key":"2019103013422116500_CIT0049","unstructured":"Borchmann P , TamCS, J\u00e4gerUet al An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Abstract S799. Presented at 23rd Congress of the European Hematology Association. Stockholm, Sweden: 2018 June 16."},{"key":"2019103013422116500_CIT0050","unstructured":"Cavallo J . Weighing the cost and value of CAR T-cell therapy. A roundtable discussion with Carl H. June, MD; Sagar Lonial, MD; David G. Maloney, MD, PhD; and Pascal Touchon.http:\/\/www.ascopost.com\/issues\/may-25-2018\/weighing-the-cost-and-value-of-car-t-cell-therapy\/ (accessed 2018 Dec 1)."},{"key":"2019103013422116500_CIT0051","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"2019103013422116500_CIT0052","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-cell receptor signaling for anticancer therapy: the bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0053","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ni.2094","article-title":"Malignant pirates of the immune system","volume":"12","author":"Rui","year":"2011","journal-title":"Nat Immunol."},{"key":"2019103013422116500_CIT0054","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood."},{"key":"2019103013422116500_CIT0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu Rev Immunol."},{"key":"2019103013422116500_CIT0056","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"De Claro","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2019103013422116500_CIT0057","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature."},{"key":"2019103013422116500_CIT0058","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11899-012-0127-0","article-title":"The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways","volume":"7","author":"Kenkre","year":"2012","journal-title":"Curr Hematol Malig Rep."},{"key":"2019103013422116500_CIT0059","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol."},{"key":"2019103013422116500_CIT0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"2019103013422116500_CIT0061","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0062","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","article-title":"BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-\u03baB","volume":"25","author":"Rushworth","year":"2013","journal-title":"Cell Signal."},{"key":"2019103013422116500_CIT0063","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrd3656","article-title":"Trial watch: BTK inhibitor shows positive results in B cell malignancies","volume":"11","author":"Harrison","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"2019103013422116500_CIT0064","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019103013422116500_CIT0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0066","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res."},{"key":"2019103013422116500_CIT0067","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O\u2019Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2019103013422116500_CIT0068","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol."},{"key":"2019103013422116500_CIT0069","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica."},{"key":"2019103013422116500_CIT0070","article-title":"Imbruvica (ibrutinib) prescribing information","year":"2019"},{"key":"2019103013422116500_CIT0071","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2018-08-865659","article-title":"Ibrutinib and Aspergillus: a BTK-targeted risk","volume":"132","author":"Woyach","year":"2018","journal-title":"Blood."},{"key":"2019103013422116500_CIT0072","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet."},{"key":"2019103013422116500_CIT0073","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2019103013422116500_CIT0074","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med."},{"key":"2019103013422116500_CIT0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-12-10","article-title":"Frequent copy number variations of PI3K\/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma","volume":"12","author":"Cui","year":"2014","journal-title":"J Transl Med."},{"key":"2019103013422116500_CIT0076","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood."},{"key":"2019103013422116500_CIT0077","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-\u03b4 in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Herman","year":"2011","journal-title":"Blood."},{"key":"2019103013422116500_CIT0078","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20120015","article-title":"Follicular lymphoma - treatment and prognostic factors","volume":"34","author":"Luminari","year":"2012","journal-title":"Rev Bras Hematol Hemoter."},{"key":"2019103013422116500_CIT0079","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.12.56","article-title":"Targeting the PI3K pathway for cancer therapy","volume":"4","author":"Sadeghi","year":"2012","journal-title":"Future Med Chem."},{"key":"2019103013422116500_CIT0080","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science."},{"key":"2019103013422116500_CIT0081","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood."},{"key":"2019103013422116500_CIT0082","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0083","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"2019103013422116500_CIT0084","article-title":"Zydelig (idelalisib) prescribing information","year":"2018"},{"key":"2019103013422116500_CIT0085","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood."},{"key":"2019103013422116500_CIT0086","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood."},{"key":"2019103013422116500_CIT0087","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell."},{"key":"2019103013422116500_CIT0088","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj3330471","article-title":"Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling","volume":"333","author":"Shepherd","year":"1998","journal-title":"Biochem J."},{"key":"2019103013422116500_CIT0089","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1158\/1078-0432.CCR-14-3262","article-title":"Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408\/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed\/refractory lymphoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2019103013422116500_CIT0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther."},{"key":"2019103013422116500_CIT0091","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0092","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science."},{"key":"2019103013422116500_CIT0093","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell Signal."},{"key":"2019103013422116500_CIT0094","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood."},{"key":"2019103013422116500_CIT0095","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","article-title":"Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing","volume":"173","author":"Reif","year":"2004","journal-title":"J Immunol."},{"key":"2019103013422116500_CIT0096","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature."},{"key":"2019103013422116500_CIT0097","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature."},{"key":"2019103013422116500_CIT0098","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"Van Attekum","year":"2017","journal-title":"Haematologica."},{"key":"2019103013422116500_CIT0099","doi-asserted-by":"crossref","first-page":"42130","DOI":"10.18632\/oncotarget.6239","article-title":"Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCS): implications for neoplastic cell survival","volume":"6","author":"Trimarco","year":"2015","journal-title":"Oncotarget."},{"key":"2019103013422116500_CIT0100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood."},{"key":"2019103013422116500_CIT0101","author":"Clinicaltrials.gov."},{"key":"2019103013422116500_CIT0102","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood."},{"key":"2019103013422116500_CIT0103","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1080\/10428194.2016.1185789","article-title":"Current and future immunotherapeutic approaches in Hodgkin lymphoma","volume":"57","author":"Br\u00f6ckelmann","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"2019103013422116500_CIT0104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-018-0601-9","article-title":"Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol."},{"key":"2019103013422116500_CIT0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14737140.2016.1121812","article-title":"Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab","volume":"16","author":"Villasboas","year":"2016","journal-title":"Expert Rev Anticancer Ther."},{"key":"2019103013422116500_CIT0106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Maly","year":"2016","journal-title":"Eur J Haematol."},{"key":"2019103013422116500_CIT0107","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"2019103013422116500_CIT0108","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0109","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol."},{"key":"2019103013422116500_CIT0110","author":"National Comprehensive Cancer Network"},{"key":"2019103013422116500_CIT0111","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappab activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med."},{"key":"2019103013422116500_CIT0112","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/onc.2013.565","article-title":"Mechanisms and consequences of constitutive NF-\u03baB activation in B-cell lymphoid malignancies","volume":"33","author":"Nagel","year":"2014","journal-title":"Oncogene."},{"key":"2019103013422116500_CIT0113","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood.V128.22.4639.4639","article-title":"Lenalidomide maintenance after autologous stem cell transplant in patients with high-risk relapsed\/refractory lymphomas is feasible and compares favorably to historical controls: results of a phase I\/II trial","volume":"128","author":"Svoboda","year":"2016","journal-title":"Blood."},{"key":"2019103013422116500_CIT0114","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol."},{"key":"2019103013422116500_CIT0115","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/carcin\/bgl092","article-title":"Discovery of novel epigenetic markers in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Shi","year":"2007","journal-title":"Carcinogenesis."},{"key":"2019103013422116500_CIT0117","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov."},{"key":"2019103013422116500_CIT0118","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol Ther."},{"key":"2019103013422116500_CIT0119","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0120","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): results from the BELIEF trial","volume":"31","author":"O\u2019Connor","year":"2013","journal-title":"J Clin Oncol."},{"key":"2019103013422116500_CIT0121","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1615\/CritRevImmunol.v15.i3-4.60","article-title":"T lymphocyte migration: the influence of interactions via adhesion molecules, the T cell receptor, and cytokines","volume":"15","author":"Hauzenberger","year":"1995","journal-title":"Crit Rev Immunol."},{"key":"2019103013422116500_CIT0122","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/84293","article-title":"Psoriasis: the plot thickens","volume":"2","author":"Sch\u00f6n","year":"2001","journal-title":"Nat Immunol."},{"key":"2019103013422116500_CIT0123","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med."},{"key":"2019103013422116500_CIT0124","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.4049\/jimmunol.178.6.3358","article-title":"Cutting edge: chemokine receptor CCR4 is necessary for antigen-driven cutaneous accumulation of CD4 T cells under physiological conditions","volume":"178","author":"Campbell","year":"2007","journal-title":"J Immunol."},{"key":"2019103013422116500_CIT0125","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J Invest Dermatol."},{"key":"2019103013422116500_CIT0126","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood."},{"key":"2019103013422116500_CIT0127","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2019103013422116500_CIT0128","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res."},{"key":"2019103013422116500_CIT0129","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem."},{"key":"2019103013422116500_CIT0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/22\/1825\/30331718\/zxz202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/22\/1825\/30331718\/zxz202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T22:04:32Z","timestamp":1664575472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/22\/1825\/5580565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":130,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2019,10,3]]},"published-print":{"date-parts":[[2019,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz202","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,15]]},"published":{"date-parts":[[2019,10,3]]}}}